Clinical Trial

Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy.

Study acronym: ZYMOT2
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
It has been described that 11% of men with semen values within the normal range established by the World Health Organization (WHO) have sperm DNA fragmentation. This has been associated with a lower fertilization rate, lower embryo development and, therefore, lower reproductive success. Focusing on the study of the integrity of the male genome can provide us information to diagnose infertility in the couple. The use of conventional sperm selection methods such as swim-up or density gradients has been a great advance in the improvement of male fertility. However, these methods use centrifugation in their protocol, a procedure that has been associated with sperm DNA damage. The ZyMōt is a chip based on microfluidic properties that allows the recovery of spermatozoa with lower DNA fragmentation rate without centrifugation of the semen sample. This new sperm selection method maintains all the advantages of conventional techniques, but decreasing DNA fragmentation associates to sperm recoveries techniques eventually improving reproductive rates. This quality would be beneficial for patients with unexplained infertility, recurrent pregnancy loss or clinical varicocele, factors that have been associated with a higher index of DNA fragmentation. However up to date there is evidence-based data supporting such improvement. The main objective of the present project is to evaluate the ZyMōt as a new non-invasive sperm selection device and to see its impact on the euploidy rate, comparing it with a sperm selection technique that is routinely used in the clinic: swim-up. At the same time, the effect that this new chip may have on sperm and other reproductive variables will be analyzed clinically, and molecularly with immunohistochemical and transcriptomic analyses in order to observe the impact of SDF(sperm DNA fragmentation) at the molecular and genomic level in oocytes with low reparative potential oocytes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-23.
Trial Details
NCT Number NCT06384794
Lead Sponsor Instituto Valenciano de Infertilidad, IVI VALENCIA
Collaborators: IVI Madrid
Conditions Infertility, Male, Sperm Count, Low
Enrollment 80 participants
Start Date 2023-06-29
Primary Completion 2025-07-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-29